Press Room
Press Releases 2024
Thursday, 14 November 2024 19:55
Bonus Biogroup Presents at the Advanced Therapies Conference USA 2024: Two-Fold Success: Enhancing Patient Care Efficiency While Reducing Costs Compared to Alternative Treatments
Bonus Biogroup is pleased to announce that it was invited to present its pioneering approach to developing advanced, safe, and effective treatments for complex medical conditions with unmet clinical needs[1]. This presentation was part of a session on clinical trials and development held on January 13, 2024, at the Advanced…
Wednesday, 30 October 2024 19:41
ISRAEL MINISTRY OF HEALTH CERTIFIES THAT BONOFILL AND MESENCURE ARE PRODUCED IN COMPLIANCE WITH GOOD MANUFACTURING PRACTICES, AS RECOMMENDED BY THE WORLD HEALTH ORGANIZATION
Bonus Biogroup is pleased to announce that on October 29, 2024, the Israel Ministry of Health (MOH) issued a certification that the Company's two products, BonoFill—a live human bone graft—and the cellular therapy MesenCure, are manufactured by the Company through an industry-standard process conducted under Good Manufacturing Practices (GMP) for…
Bonus Biogroup is pleased to announce that on June 18, 2024, at the annual meeting of the International Society for Applied Biological Sciences (ISABS) [1], the Company disclosed that, pursuant to an outline agreed upon with the U.S. FDA, it has successfully completed the development of a unique quality control…
Bonus Biogroup is pleased to announce that on May 31, 2024, it presented at a special session [1] at the annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, the results of a Phase II clinical trial for treating facial bone deficiencies in the…
Sunday, 19 May 2024 09:38
Bonus Biogroup Invited to Present Final Results of Phase II Clinical Trial for Treating Facial Bone Deficiencies Using BonoFill™ at the Annual Meeting of the International Society for Cell and Gene Therapy
Bonus Biogroup is pleased to announce that it will present the final results of a Phase II clinical trial for treating facial bone deficiencies in the upper or lower jaw bones using BonoFill™—a live human bone graft manufactured by the Company (hereinafter: "Clinical Trial to Treat Facial Bone Deficiencies"). This…
Wednesday, 14 February 2024 05:00
Bonus Biogroup Empowers Organ Developers with Infrastructure for Branched Artificial Blood Vessels to Enhance Acceptance of Engineered Organs
Patents Granted in Europe and the UK, Following Earlier Approvals in the US, Australia, and China, Position the Company at the Forefront of Engineered Organ Development and Commercialization Bonus Biogroup is pleased to announce the approval of patents by the European and UK Patent Offices, covering 17 European countries and…
Sunday, 21 January 2024 06:02
A First: Israeli Company Wins the World's Advanced Therapies Award
Bonus Biogroup Recognized as a Global Leader in Biotechnology and Cell Therapy at Advanced Therapies Week 2024 in Miami, USA Bonus Biogroup is proud to announce its remarkable achievement on January 18, 2024, having been awarded the prestigious Advanced Therapies Award in the foremost category: Cell Therapy Biotech Innovation [1].…
Wednesday, 10 January 2024 13:39
Patent Approved in Japan Expands Protection for Exclusive Use and Commercialization of BonoFill, a Living Human Bone Graft, in Japan's $24 Billion Bone Deficiency Treatment Market
Bonus Biogroup is pleased to announce that the Japan Patent Office has granted a patent providing Bonus Therapeutics, a wholly-owned subsidiary of the Company, exclusive rights to use and commercialize cell characterization for transplantation [1]. These specialized cells are integral to "BonoFill," a living human bone graft developed by Bonus…
info@bonus-bio.com
+972 (0)73 206 7104
Matam Advanced Technology
Park P.O.B 15143 Haifa 31905 Israel
 |
 |
 |
 |
© 2022 Bonus BioGroup Ltd. Created By Netron Israel Ltd